CHICAGO — Rod Humerickhouse, MD, PhD, asset strategy leader for venetoclax at AbbVie, spoke with HemOnc Today at ASCO Annual Meeting about results of the phase 3 CLL14 study.
The results, presented at ASCO, showed the combination of venetoclax (Venclexta; AbbVie, Genentech) and obinutuzumab (Gazyva, Genentech) extended PFS and induced higher rates of complete response compared with a commonly used regimen of obinutuzumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia.
The combination also demonstrated an effect on minimal residual disease that had never before been reported in CLL, Humerickhouse said.
“This really does support the idea that you can treat patients for a fixed duration, stop therapy and have long sustained progression-free intervals, which both patients and physicians value,” he told HemOnc Today.
Humerickhouse also provided an overview of the company’s pipeline and the key research focus areas over the next year and beyond. – by Mark Leiser